Overview

Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

Status:
Completed

Trial end date:
2008-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the effectiveness and safety of galantamine hydrobromide treatment in patients with severe Alzheimer's disease.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Pharmaceutica N.V., Belgium

Treatments:

Galantamine